BioMelbourne Network
Progressing BioIndustry
Latest News
Melbourne Pathology to be First Australian Site to use Breakthrough Microbiology System
• Australian innovation already sold in US, Europe and Asia
• Changes microbiology labs into automated workplaces
1 July 2010: Melbourne Pathology is the first Australian laboratory to acquire PREVI™ Isola. Distributed by bioMérieux Australia Pty Ltd, PREVI™ Isola is based on LBT Innovations Limited (ASX: LBT) revolutionary MicroStreak® technology for automated agar plate streaking in microbiology laboratories.
Melbourne Pathology is a Sonic-owned laboratory providing services to GP’s, medical specialists, nursing homes and private hospitals in greater Melbourne and regional Victoria,
bioMérieux Australia Managing Director, Paul Wilson, said, “This system has been very well received in those laboratories around the world that have already adopted this technology and we are pleased to see PREVI™ Isola launched in Australia”.
Mr Wilson added, “Automation represents the biggest step forward for microbiology labs in at least fifty years.”
“This advance will not only alleviate workloads for thousands of scientists around the world, it will help to improve health outcomes for patients.”
LBT Innovations’ CEO and Managing Director, Lusia Guthrie, said, “This technology has the potential to radically change the way infectious diseases laboratories operate. It streamlines laboratory processes and gives superior results for patients. This is a huge step forward and we are thrilled that the system is now being installed in Australian laboratories."
PREVI™ Isola was recently a winning product in this year’s MDEA medical design excellence awards competition, receiving gold recognition in its class at a ceremony held last month at the Jacob K Javits Convention Center in New York City.
The sale of the first PREVI™ Isola in Australia triggers a milestone payment of $20,000 by LBT Innovations to Medvet Science Pty Ltd from whom the core technology was licensed.
—ENDS—
About LBT Innovations
LBT Innovations is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company was formed in 2004 and listed on the Australian Securities Exchange on 31 July 2006 (ASX: LBT). The focus of the company has been the commercialisation of its first product, known as MicroStreak®.
In 2007, LBT Innovations signed an agreement with French diagnostics giant bioMérieux to commercialise and market this invention, which is now known as PREVI™ Isola. This instrumentation product comprises a central part of bioMérieux’s FMLA™ (Full Microbiology Lab Automation™) strategy.
Going forward, LBT Innovations intends to continue its track record of innovation in microbiology, while also fully exploiting its existing commercial relationships and intellectual property portfolio.
For more information, see www.lbtinnovations.com
CONTACTS
LBT Innovations
Lusia Guthrie
CEO & MD
Tel: +61 (0) 8 8227 1555
E: info@lbtinnovations.com
bioMérieux Australia Pty Ltd
Paul Wilson
Managing Director
Mobile: 0418 545 012
Media Relations
Emma Power / Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333
E: emmap@monsoon.com.au
